Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23482805 | 0.80 | FOLH1 (0.38) | MAPTFOLH1NAALAD2ALDH1A1KMT2A | |
| SCHEMBL23193782 | 0.78 | FOLH1 (0.36) | MAPTFOLH1NAALAD2ALDH1A1KMT2A | |
| SCHEMBL19401581 | 0.77 | MMP2 (0.43) | MAPTFOLH1MMP2MMP9MMP8 | |
| SCHEMBL13947584 | 0.77 | — | — | |
| SCHEMBL17715215 | 0.77 | — | — | |
| SCHEMBL3367018 | 0.77 | — | — | |
| SCHEMBL10475828 | 0.76 | MEN1 (0.49) | KMT2AMEN1 | |
| SCHEMBL10475827 | 0.76 | MEN1 (0.49) | KMT2AMEN1 | |
| SCHEMBL17616111 | 0.75 | CA2 (0.38) | MAPTFOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL19401717 | 0.75 | GNPAT (0.33) | MAPTFOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CYP2D6 4022/4885CYP2C19 4450/4885MAPT 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.